Table 1: Currently available DAA agents, common adverse events, renal and hepatic function considerations.

Drug	Brand Name	HCV genotype	Adverse Event Reported > 10%	Renal function limits	Hepatic function limits
Simeprevir	Olysio®	1 when combined with sofosbuvir	Photosensitivity, fatigue, headache, dizziness, insomnia, nausea, increased bilirubin, diarrhea, myalgia, dyspnea	None	Avoid in decompensated cirrhosis or Child-Pugh B or C
Sofosbuvir	Sovaldi®	1 when combined with ledipasvir, 3 when combined with daclatasvir	Fatigue, nausea, headache, insomnia, weakness	Not recommended for CrCl < 30 ml/min	None
Ledipasvir/Sofosbuvir	Harvoni®	1 and 4	Headache, fatigue, insomnia	Not recommended for CrCl < 30 ml/min	None
Ombitasvir/Paritaprevir Ritonavir/Dasabuvir	Viekira Pak™ Viekira XR^TM	1	Fatigue, headache, insomnia, rash, pruritis, diarrhea, nausea, anemia, increased bilirubin, increased ALT, weakness, muscle spasm, cough	None	Avoid in decompensated cirrhosis or Child-Pugh B or C
Daclatasvir	Daklinza™	3 when combined with sofosbuvir	Fatigue, nausea, headache, anemia	None	None
Ombitasvir/Paritaprevir Ritonavir	Technivie™	4	Fatigue, insomnia, rash, pruritis, nausea, increased ALT, anemia	None	Avoid in decompensated cirrhosis or Child-Pugh B or C
Elbasvir/Grazoprevir	Zepatier™	1 & 4	Fatigue, headache, nausea	None	Avoid in decompensated cirrhosis or Child-Pugh B or C
Sofosbuvir/Velpatasvir	Epclusa®	1,2,3,4,5 & 6	Headache, fatigue	Not recommended for CrCl < 30 ml/min	None
Data obtained from product package insert [27,33,34,46-51].